Ikena Oncology, Inc. — Q1 2021 Form 10-Q
Filing identity: The supplied filing is for Ikena Oncology, Inc. (Nasdaq: IKNA), not Imagenebio, Inc. Confirm that this is the intended company.
Business context and reporting period
This unaudited report covers the three months ended March 31, 2021, with comparisons to Q1 2020. Ikena is a targeted oncology drug developer with no approved products and no product-sales revenue. Its programs include wholly owned candidates and a Bristol Myers Squibb (BMS) collaboration. The quarter included Ikena’s March 2021 IPO and conversion of all outstanding redeemable convertible preferred stock into common stock.
Key financial metrics
| Metric | Q1 2021 | Q1 2020 / prior date |
|---|---|---|
| Collaboration revenue | $3.5 million | $3.2 million |
| Research and development expense | $10.0 million | $7.9 million |
| General and administrative expense | $3.2 million | $2.5 million |
| Total operating expenses | $13.2 million | $10.4 million |
| Operating loss | $9.7 million | $7.2 million |
| Net loss | $9.7 million | $6.9 million |
| Basic and diluted net loss per share | $2.52 | $2.62 |
| Net cash used in operating activities | $13.2 million | $9.9 million |
| Cash and cash equivalents at period end | $281.0 million | $162.5 million at Dec. 31, 2020 |
At March 31, total assets were $293.7 million and total liabilities were $66.0 million. The filing reports no borrowings or debt balance. Revenue was entirely collaboration revenue; product revenue was zero. Gross margin is not presented, and a conventional product margin is not meaningful for this pre-commercial business.
Operating cash outflow was $13.2 million and investing cash outflow was $0.8 million. Financing activities provided $132.5 million, primarily from the IPO. Cash, cash equivalents and restricted cash totaled $281.9 million, including $0.9 million of restricted cash. The company reported an accumulated deficit of $121.1 million.
Material changes versus the prior comparable period
- Revenue rose by $0.2 million, reflecting increased BMS program activity.
- R&D expense increased $2.1 million, principally from continued IK-930 and IK-412 development and manufacturing work, other discovery programs, and higher personnel and overhead costs. Lower IK-175 manufacturing and IK-007 clinical costs partly offset the increase.
- G&A expense increased $0.7 million, driven by headcount and public-company audit, legal and consulting costs.
- Net loss increased $2.8 million; operating cash use increased $3.3 million.
- The IPO raised approximately $143.8 million gross and $131.3 million net, per management’s discussion. Preferred shares converted into 23.7 million common shares. The company also effected a 1-for-7.154 reverse stock split.
Outlook, management commentary, risks and unusual items
- Management expects continuing operating losses and negative operating cash flow as R&D expands. It estimates cash will fund operations and capital expenditures through 2023; the financial-statement liquidity discussion separately says cash should cover at least the next 12 months. Both are estimates subject to execution and spending risks.
- Development plans included an IK-930 IND filing in the second half of 2021; ERK5 candidate nomination and IND-enabling work in the second half of 2021, with an IND targeted for the second half of 2022; and an IK-412 IND filing targeted for the second half of 2021. IK-175 was in Phase 1 and IK-007 in Phase 1b. These are forward-looking plans, not achieved milestones.
- COVID-19 had caused some clinical-site closures and enrollment delays, which management said had not materially affected development timelines as of the filing. Further disruption remained a risk.
- Under the BMS collaboration, Ikena recognized $3.5 million of revenue in Q1 from previously deferred amounts. Deferred BMS revenue was $52.3 million at quarter end. BMS may elect licenses for IK-175 and IK-412; potential option, milestone and royalty payments depend on future events and are not assured.
- The new Boston headquarters lease commenced in February 2021: 63 months, approximately $9.3 million in total minimum payments, with a $0.9 million letter of credit.
- Key risks include early-stage drug-development and regulatory uncertainty, clinical-trial enrollment and safety outcomes, reliance on third-party manufacturers and single-source API suppliers, collaboration-partner decisions, intellectual-property protection, and the need for future financing. No material litigation was reported. Disclosure controls were assessed as effective at the reasonable-assurance level.
Important facts for investors to verify
- Confirm the intended issuer: the filing is Ikena Oncology, whereas the request metadata names Imagenebio.
- Track actual IND submissions, trial starts and results against the stated development timelines, particularly for IK-930 and IK-412.
- Assess quarterly cash burn and spending relative to management’s through-2023 runway estimate; the filing states there is no committed external funding source.
- Review BMS option decisions, research-term obligations and the timing and recognition of the $52.3 million deferred revenue balance.
- Reconcile IPO proceeds across the narrative and cash-flow presentation, and monitor dilution from outstanding options and equity plans.